Efficacy and Safety of insulin degludec/aspart (RyzoDeg) in Type 2 Diabetes Mellitus in Pakistan: Real-Life Experience

Abstract

Background: Insulin Degludec/Aspart (IDeg/Asp) is a novel insulin co-formulation launched in Pakistan in 2018 containing Insulin Degludec and aspart in a 70/30 ratio that can be given once daily or twice daily.

Objectives: This study aimed was to look at the efficacy and safety of IDeg/Asp in real-life Pakistani population with Type 2 Diabetes mellitus in a secondary care setting in Islamabad, Pakistan.

Methods: A 12-week multi-centric observational cohort study was performed at different hospitals in Islamabad, Pakistan with 105 patients who were prescribed IDeg/Asp. The data was collected from T2DM patients having HbA1C ≥ 7.0% and aged between 40-70 years. The primary of the study was a decrease in HbA1C from the base-line and secondary end-points include change in body weight, fasting plasma glucose level, postprandial glucose level, hypoglycemic episodes and adherence to the treatments. The statistical analysis was carried out through a paired T-test.

Results: Baseline HbA1c, fasting glucose, post-prandial glucose and weight were 8.48±1.27%, 201.05±44.41 mg/dl, 266.67±58.45 mg/dl and 79.18±17.69 kg respectively. At the end of 12 weeks, there was a mean reduction in HbA1c by 1.79% to 6.69±0.52%, fasting glucose reading by 78 mg/dl to 123.33±24.68 mg/dl and post-prandial glucose by 95 mg/dl to 171.62±30.73 mg/dl. There was minimal weight loss with the weight coming down by a mean of 1.62 kg to 77.56±16.13 kg. There was only 1 patient who experienced hypoglycemia. Similarly, All the participants were well adhered to their treatments throughout the study duration as per the Morisky-Green-Levine test.

Conclusion: This real-life observational study on the use of IDeg/Asp in a Pakistani population with Type 2 Diabetes mellitus have shown that once or twice daily IDeg/Asp is significantly more effective in hyperglycemia management with lesser side effects in people with uncontrolled Type 2 Diabetes mellitus.

How to cite this: Shafique ME, Raja UY, Saqlain M, Fakhar ud Din, Ishtiaq A, Khan GM, et al. Efficacy and Safety of Insulin degludec/aspart (RyzoDeg) in Type 2 Diabetes Mellitus in Pakistan: Real-Life Experience. JPES. 2024;1(2):53-57.